Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!
- 31 August 2023
- journal article
- editorial
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (4) , e1365-e1366
Abstract
George P Chrousos; Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses are still an Open Chapter!, The Journal of ClinicalKeywords
This publication has 8 references indexed in Scilit:
- Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal HyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 2023
- Congenital adrenal hyperplasiaThe Lancet, 2022
- Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal HyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 2021
- The neuroendocrinology of stress: the stress-related continuum of chronic disease developmentMolecular Psychiatry, 2021
- Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 StudiesThe Journal of Clinical Endocrinology & Metabolism, 2021
- Stress and disorders of the stress systemNature Reviews Endocrinology, 2009
- Potential Uses of Corticotropin‐Releasing Hormone AntagonistsAnnals of the New York Academy of Sciences, 2006
- Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonistsTrends in Endocrinology & Metabolism, 2002